HLB, HK inno.N and Hanmi Pharm announce overseas expansion and investment plans in succession
HLB 2026 will 5 at 22 announce new liver and bile duct cancer drugs at the American Cancer Society’s annual meeting, with a solo booth.970 The company said it will invest to meet global demand for K-CAB at its Osong plant.
HLB 2026 will 5 at 22 introduce new treatments for liver and bile duct cancers at the American Cancer Society’s annual meeting. The company plans to present clinical results and development progress at its booth. It will promote its products to overseas medical professionals by participating with a solo booth.
Pony.ai is accelerating the commercialization of robotaxis in China. The company is moving to expand the operating zones and operating examples of its autonomous driving service. It is pursuing broader commercialization by unveiling related technologies and operating cases.
HK inno.N 2026 will 5 at 21 announce an investment in its Osong plant. The investment is earmarked for expanding facilities to meet global demand for K-CAB products. The company is detailing plans to expand the plant and increase production capacity.970 The investment is aimed at meeting global demand for K-CAB products.
TIME launches an ETF investing in global robotics-related stocks. The ETF pools companies in the robotics sector for investment. The K Savings Bank is offering a savings product with an annual interest rate of 4.7%.
Thailand is introducing crypto ETFs. The government and relevant institutions are pursuing the introduction of a regulatory framework to strengthen the country's competitiveness as a digital asset hub. Related regulations and investor protection measures are also being discussed.
Hanmi Pharmaceutical announced plans to export combination drugs to Southeast Asia with Organon. The company is discussing the export destinations and contract terms. Product approvals and local distribution plans are also being prepared in parallel.3 types.